March 13, 2014
(Stock Blog Hub, 10/23/12)
Consistent uptrend in Oncotype sales, pipeline development, strategic investments and impressive second quarter performance have helped Genomic Health (GHDX), a global cancer company, to...(read more)
(Stock Blog Hub, 12/1/11)
Genomic Health (GHDX), an oncology based biotech company, will present results from 16 studies at the San Antonio Breast Cancer Symposium in December. The company has been recording...(read more)
(Stock Blog Hub, 7/23/10)
Genomic Health's (GHDX) first quarter 2010 loss of $0.07 per share missed the Zacks Consensus Estimate of a loss of $0.03. Although the company's lead product, Oncotype DX breast...(read more)
Genomic Health (GHDX) Company Overview
There is no analysis for GHDX yet. But you can go to Wikinvest to help create one!
What's in this GHDX analysis on Wikinvest...